The safety and effectiveness of sintilimab versus camrelizumab, both plus targeted drugs, in advanced hepatocellular carcinoma

The safety and effectiveness of sintilimab versus camrelizumab, both plus targeted drugs, in advanced hepatocellular carcinoma

ObjectivesWe aimed to evaluate the effectiveness and safety of sintilimab versus camrelizumab, both plus targeted drugs, for advanced hepatocellular carcinoma (HCC) in the real world. Then the effectiveness was compared between sintilimab-lenvatinib and camrelizumab-apatinib.MethodsPatients diagnose...

Full description

Saved in:

Bibliographic Details
Main Authors:	Chenglong Zhao, Qiongni Zhu, Xiaoyan Qian, Zhonghua Fu, Wei Zhang, Yaqin Wang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-06-01
Series:	Frontiers in Immunology
Subjects:	sintilimab camrelizumab hepatocellular carcinoma survival analysis real-world study
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1585956/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Transarterial Chemoembolization Plus Camrelizumab and Rivoceranib versus Camrelizumab and Rivoceranib Alone for BCLC Stage C Hepatocellular Carcinoma
by: Zhou WJ, et al.
Published: (2024-12-01)

Cost-effectiveness of camrelizumab plus rivoceranib for advanced hepatocellular carcinoma in the context of regional disparities in China
by: Zhonghua Zhao, et al.
Published: (2024-12-01)

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for patients with unresectable hepatocellular carcinoma: a cost–utility analysis in China and the United States
by: Qiuling Zhao, et al.
Published: (2025-05-01)

Matching-adjusted indirect comparison of tislelizumab plus lenvatinib versus sintilimab plus bevacizumab biosimilar as first-line treatment for unresectable hepatocellular carcinoma
by: Kunyuan Wang, et al.
Published: (2025-06-01)

Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study
by: Lingzhan Meng, et al.
Published: (2024-11-01)

Hepatic Arterial Infusion Chemotherapy Combined Apatinib/Camrelizumab for Recurrent Hepatocellular Carcinoma After Hepatectomy
by: Zheng X, et al.
Published: (2025-06-01)

Efficacy and Safety of Hepatic Artery Infusion Chemotherapy Combined with Donafenib and Camrelizumab in the Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Retrospective, Single-Arm Study
by: Wu C, et al.
Published: (2025-07-01)

Case Report: Durable complete response of advanced-stage hepatocellular carcinoma to DEB−TACE combined with lenvatinib and camrelizumab
by: Baiguo Xu, et al.
Published: (2025-06-01)

Long survival after neoadjuvant and adjuvant camrelizumab plus chemotherapy and surgery in a patient with hepatoid adenocarcinoma of the lung: A case report
by: Xuhua Huang, et al.
Published: (2024-12-01)

Predictors of recurrence after conversion therapy in unresectable hepatocellular carcinoma treated with HAIC, bevacizumab, and sintilimab
by: Chang-Fu Liu, et al.
Published: (2025-08-01)

Hepatic artery infusion of FOLFOX chemotherapy plus camrelizumab combined with sorafenib for advanced hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (Double-IA-001): a phase II trial
by: Lujun Shen, et al.
Published: (2025-05-01)

Hepatic artery infusion chemotherapy combined with camrelizumab and apatinib as conversion therapy for patients with unresectable hepatocellular carcinoma: a single-arm exploratory trial
by: Kugeluke Yalikun, et al.
Published: (2025-05-01)

Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial
by: Xiaoyang Hong, et al.
Published: (2025-02-01)

Use of camrelizumab in treatment of nasopharyngeal carcinoma
by: Yu. V. Alymov, et al.
Published: (2024-12-01)

Case Report: Camrelizumab plus gemcitabine followed by concurrent chemoradiation for HPV-positive and PD-L1-positive tonsillar squamous cell carcinoma
by: Xuesong Li, et al.
Published: (2025-03-01)

Efficacy and safety of camrelizumab plus Lacticaseibacillus paracasei in the treatment of advanced esophageal squamous cell carcinoma: A single-arm, single-center, exploratory trial
by: Tengfei Zhang, et al.
Published: (2025-07-01)

Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab versus neoadjuvant chemotherapy plus tislelizumab for locally advanced esophageal squamous cell cancer: a real-world retrospective study
by: Qi Zhao, et al.
Published: (2025-08-01)

Real-World, Observational, Retrospective Study to Evaluate the Effectiveness and Safety of Treatment with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
by: Angélica Richart Csipak, et al.
Published: (2024-11-01)

Induction chemotherapy plus camrelizumab combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma in non-endemic areas: a phase 2 clinical trial in North China
by: Zhongqiu Wang, et al.
Published: (2025-02-01)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy for locally advanced rectal cancer: 3-year survival from a phase 2 study
by: Zhenyu Lin, et al.
Published: (2025-05-01)

Camrelizumab-based therapies for the treatment of advanced lung cancer: a prospective, open-label, multicenter, observational, real-world study
by: Dong Zhao, et al.
Published: (2025-03-01)

Camrelizumab combined with apatinib plus irinotecan as a second-line treatment in advanced or metastatic esophageal squamous cell carcinoma patients
by: Shusheng Wu, et al.
Published: (2025-05-01)

Transarterial chemoembolization combined with apatinib in the treatment of advanced hepatocellular carcinoma: a prospective, multi-center, real-world study (Ahend-HAP02)
by: Hang Yuan, et al.
Published: (2025-07-01)

Efficacy and safety of camrelizumab for the treatment of cervical cancer: a systematic review and meta-analysis
by: Xiaodong Mi, et al.
Published: (2024-12-01)

Case report: Chemotherapy plus sintilimab for the treatment of gastroesophageal junction hepatoid adenocarcinoma with liver metastasis: a case study with literature review
by: Genlin Lu, et al.
Published: (2025-01-01)

Camrelizumab, an Anti‐PD‐1 Monoclonal Antibody, Plus Carboplatin and Nab‐Paclitaxel as First‐Line Setting for Extensive‐Stage Small‐Cell Lung Cancer: A Phase 2 Trial and Biomarker Analysis
by: Jia Yu, et al.
Published: (2025-08-01)

Neoadjuvant sintilimab and chemotherapy for resectable esophageal squamous cell carcinoma: a phase II clinical trial
by: Jincheng Guo, et al.
Published: (2025-04-01)

Neoadjuvant camrelizumab plus chemotherapy or apatinib for resectable stage IIA–IIIA NSCLC: a multicenter, two-arm, phase II exploratory trial
by: Shuyu Ji, et al.
Published: (2025-07-01)

Safety and efficacy of sintilimab versus pembrolizumab in the treatment of advanced or recurrent pediatric malignancies: a real-world study in China
by: Lei Mao, et al.
Published: (2025-06-01)

Fruquintinib and sintilimab plus SOX as perioperative therapy for locally resectable advanced gastric/gastroesophageal junction adenocarcinoma: study protocol for a prospective, single-arm, phase II clinical trial
by: Xiangyu Meng, et al.
Published: (2025-07-01)

Hyperprogression disease induced by Sintilimab combined with Oxaliplatin and S-1 after surgery: a case report and literature review
by: Yaoqi Li, et al.
Published: (2025-06-01)

Long-term efficacy and updated survival outcomes of sintilimab plus anlotinib in patients with PD-L1-positive recurrent or metastatic cervical cancer
by: Jing Liu, et al.
Published: (2025-07-01)

A case report: interstitial pneumonia following treatment of gastric cancer with sintilimab in combination with S-1
by: Pei Zhu, et al.
Published: (2025-02-01)

Sintilimab-induced intestinal obstruction and hemorrhage of the digestive tract: a case report
by: Qian Hao, et al.
Published: (2025-07-01)

Cost-effectiveness analysis of sintilimab additional to chemoradiotherapy in high-risk locoregionally advanced nasopharyngeal carcinoma
by: Longjiang She, et al.
Published: (2025-07-01)

A case of camrelizumab-induced anaphylaxis and successful rechallenge: a case report and literature review
by: Ping Song, et al.
Published: (2025-03-01)

Immune repertoire sequencing reveals differences in treatment response to camrelizumab plus platinum-based chemotherapy in advanced ESCC
by: Xiaoling Zhang, et al.
Published: (2025-02-01)

Case report: A golden tail of immunotherapy: significant tail effect in a chemotherapy-resistant advanced pulmonary sarcomatoid carcinoma patient treated by Sintilimab combined with Anlotinib
by: Chenghao Fu, et al.
Published: (2024-11-01)

Efficacy and safety of first‐line sintilimab plus anlotinib versus chemotherapy for metastatic non‐small cell lung cancer: a phase II, open‐label, randomized controlled trial
by: Tianqing Chu, et al.
Published: (2025-04-01)

Case Report: Multiple cutaneous keratoacanthoma-like lesions in a colorectal cancer patient treated with sintilimab
by: Shiyi Li, et al.
Published: (2025-03-01)